We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Glucose Monitoring Test Strips Improved

By LabMedica International staff writers
Posted on 24 Nov 2009
A new and improved blood glucose monitoring test strip has been launched.

The Assure Pro blood glucose monitoring system is designed for long-term care and multiresident use settings. Feature loaded, the Assure Pro meter helps facilities meet state regulatory standards and provide better resident care. The strips require 50% less blood, reducing the sample size from 1 µL to only 0.5 µL. All Assure blood glucose-monitoring systems utilize glucose oxidase (GO) strip chemistry, which is not affected by interferences that cause testing errors in other common test strips.

Assure Blood Glucose Meters are backed by the Assure Brilliance program--a comprehensive service program for diabetes management in long-term care (LTC). Assure Brilliance provides customer service, on-site training, Quality Assurance/Quality Control (QA/QC) guidance, diabetes F-Tag advice for LTC, a quarterly newsletter, online CE programs, and more to help facilities manage complex diabetes care in their facilities.

Arkray Inc. (Edina, MN, USA), a manufacturer of diabetes self-monitoring systems, launched the new and improved Blood Glucose Monitoring Test Strip. The company manufactures and distributes cost-effective products that are simple, convenient, and easy-to-use, including blood glucose meters, test strips, safety lancets, and urine chemistry.

Related Links:

Arkray Inc.



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5
New
Repetitive Pipette
VWR® Stepper Pro

Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
INTEGRA BIOSCIENCES AG